THY1 and prostate carcinoma: Zhao and colleagues reported that the marker CD90 was raised in both MSCs and in prostate cancer stromal fibroblasts, which the authors analysed by quantitative PCR after isolating them from tissues by FACS, using CD90 as a discriminator [30].